Berndt Modig Sells 2,291 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $39.40, for a total value of $90,265.40. Following the completion of the transaction, the chief executive officer owned 128,334 shares in the company, valued at approximately $5,056,359.60. This trade represents a 1.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $34.77, for a total value of $79,692.84.

Pharvaris Stock Down 1.3%

Shares of NASDAQ PHVS opened at $37.55 on Thursday. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The business has a 50 day moving average price of $35.31 and a two-hundred day moving average price of $31.63. The firm has a market cap of $2.46 billion, a PE ratio of -12.31 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on PHVS shares. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Guggenheim boosted their target price on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada upped their target price on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Citizens Jmp increased their price target on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, September 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $59.87.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently added to or reduced their stakes in the business. venBio Partners LLC bought a new stake in shares of Pharvaris during the 2nd quarter valued at about $160,569,809. 5AM Venture Management LLC bought a new position in Pharvaris in the second quarter worth about $27,581,008. BlackRock Inc. bought a new position in Pharvaris in the second quarter worth about $26,677,000. Elmind Capital LP acquired a new position in Pharvaris in the second quarter valued at approximately $18,180,435. Finally, Seven Fleet Capital Management LP boosted its stake in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after acquiring an additional 457,804 shares during the period.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
• Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
• Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.